aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
September 01, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
June 10, 2021 16:30 ET
|
aTyr Pharma, Inc.
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are...
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform
May 12, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
April 14, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...